For decades, medicine framed heart failure mainly as a cardiac pump problem. Clinicians measured ejection fraction, treated fluid retention, and grouped patients by how strongly the left ventricle contracted. That framework remains useful, but incomplete.
The 2026 European Society of Cardiology heart-failure guideline, published August 28, recognizes a broader reality. Adipose tissue, blood vessels, kidneys, muscle, glucose metabolism, blood pressure, and sleep all shape cardiac workload and reserve. The guideline therefore moves cardiometabolic care toward the center of heart-failure treatment.
A New Way to Classify Heart Failure
Ejection fraction describes the percentage of blood that the left ventricle ejects with each contraction. However, it cannot fully measure stiffness, filling pressure, or the metabolic demands placed on circulation. A seemingly normal ejection fraction therefore does not exclude serious heart failure.
The ESC now removes the intermediate category called heart failure with mildly reduced ejection fraction, or HFmrEF. It defines heart failure with reduced ejection fraction, or HFrEF, as an ejection fraction below 50%. Heart failure with preserved ejection fraction, or HFpEF, begins at 50% and also requires supporting structural or functional evidence.
Current U.S. guidance still uses HFrEF for an ejection fraction of 40% or lower and HFmrEF for 41%–49%. The same patient may therefore receive different labels under European and American systems. Good care should follow the patient’s physiology rather than a label alone.
| Area | 2026 ESC change | Practical meaning |
|---|---|---|
| Ejection fraction | HFrEF now includes values below 50%; HFpEF begins at 50% | The former 41%–49% middle category moves into the reduced-EF group |
| Core medication | Dapagliflozin or empagliflozin and an appropriate mineralocorticoid-receptor antagonist are recommended across the symptomatic HF spectrum | Treatment relies less on ejection fraction alone |
| Obesity and HF | Semaglutide or tirzepatide should be considered with symptoms, LVEF ≥45%, and BMI ≥30 kg/m², regardless of diabetes | Obesity treatment becomes part of heart-failure care |
| Prevention | Systolic pressure below 130 mmHg is recommended in hypertension or stage B pre-heart failure | Earlier risk control aims to prevent progression |
| Rehabilitation | Weight treatment now pairs with adequate protein, resistance exercise, and muscle preservation | The quality of weight loss matters as much as the quantity |
The Heart Does Not Fail Alone
The most important change involves the guideline’s organizing logic. SGLT2 inhibitors first entered medicine as glucose-lowering drugs, yet they now protect the heart and kidneys even when glucose does not drive the decision. Mineralocorticoid-receptor antagonists likewise influence sodium balance, blood pressure, fibrosis, kidney physiology, and cardiac remodeling.
These therapies show why endocrinology, nephrology, and cardiology increasingly overlap. Diabetes can promote vascular injury, kidney dysfunction can worsen congestion, and excess adipose tissue can raise inflammation, blood pressure, and sleep-apnea risk. Meanwhile, muscle loss can reduce exercise capacity even when an echocardiogram appears stable.
However, integration does not mean giving every medication to every patient. Kidney function, potassium, blood pressure, volume status, frailty, and medication tolerance still determine whether an SGLT2 inhibitor or mineralocorticoid-receptor antagonist fits safely. Modern treatment expands the framework while preserving individualized judgment.
Obesity Treatment Enters the Heart-Failure Framework
The recommendation for semaglutide or tirzepatide marks a meaningful shift. The ESC advises considering these medications in patients with symptomatic heart failure, an ejection fraction of at least 45%, and a BMI of at least 30 kg/m², even without diabetes. The intended benefits extend beyond the scale and include better symptoms, physical function, exercise capacity, and quality of life.
This approach recognizes obesity as active physiology rather than passive body weight. Reducing excess adiposity can lower mechanical load, improve blood pressure and glucose regulation, reduce inflammation, and make movement easier. Obesity treatment can therefore support the heart through several pathways at once.
Still, current evidence comes mainly from selected patients with obesity-related preserved or near-preserved ejection fraction. The studies support improvements in symptoms, function, weight, and heart-failure events, but they do not establish a mortality benefit in every heart-failure population. GLP-1 therapy should strengthen a comprehensive plan, not replace established treatment.
Weight Loss Must Preserve Strength
The companion 2026 ESC cardiac-rehabilitation guideline completes the picture. Weight loss can remove excess fat but also reduce lean tissue. A patient who becomes lighter yet weaker may lose some of the intended functional benefit.
For this reason, cardiovascular rehabilitation now integrates obesity treatment with adequate protein, resistance training, and attention to muscle preservation. Clinicians should individualize protein intake when kidney disease or another condition changes nutritional needs. The goal should remain less excess fat with preserved or improved strength, balance, and physical capacity.
How These Changes May Look in Practice
The following examples illustrate how the same guideline can lead to different decisions:
- Case 1 — Obesity-Related HFpEF: A 68-year-old woman has breathlessness, an ejection fraction of 60%, and a BMI of 36 kg/m² without diabetes. Her care may combine established therapy with semaglutide or tirzepatide while tracking symptoms, walking capacity, nutrition, and strength.
- Case 2 — The 46% Classification Shift: A 62-year-old man has an ejection fraction of 46%. U.S. terminology may call this HFmrEF, while the ESC now calls it HFrEF. His symptoms, cause, trajectory, and response still guide care.
- Case 3 — Kidney and Potassium Limits: A 75-year-old woman has symptomatic heart failure, chronic kidney disease, and high-normal potassium. An SGLT2 inhibitor may fit well, while mineralocorticoid-receptor antagonist therapy requires careful selection and close laboratory monitoring.
- Case 4 — Weight Loss With Growing Weakness: A 73-year-old woman loses meaningful weight with GLP-1 therapy but notices difficulty rising from a chair. A slower treatment pace, adequate nutrition, resistance exercise, and formal rehabilitation may protect the muscle function that supports independence.
- Case 5 — Central Sleep Apnea in HFrEF: A 70-year-old man has reduced-ejection-fraction heart failure and predominantly central sleep apnea. His team distinguishes central from obstructive apnea because the ESC continues to advise against adaptive servo-ventilation in this setting, while other sleep-related strategies require a phenotype-specific approach.
Why Holistic, Individualized Care Matters
Heart failure appears in the heart, but its causes and consequences travel through the whole body. A smart strategy connects the echocardiogram with kidney function, potassium, blood pressure, glucose, body composition, sleep, nutrition, medication tolerance, and daily function. It also addresses early risk before congestion and disability become established.
This broader viewpoint makes cardiac care more complete. The 2026 ESC guideline recognizes that effective treatment often emerges when several specialties converge on the same physiological goal.
The Takeaway
The new ESC guideline reframes heart failure as a cardiometabolic syndrome rather than an isolated pump disorder. It simplifies ejection-fraction categories, strengthens SGLT2 and mineralocorticoid-receptor antagonist therapy across the spectrum, brings obesity medication into selected heart-failure care, and makes muscle preservation part of rehabilitation. Its central lesson remains practical: successful treatment must reduce risk while preserving strength, function, and quality of life.
At our practice in Montgomery County, Maryland, and through virtual care, we evaluate heart failure risk from multiple angles, including obesity, diabetes, kidney function, blood pressure, sleep apnea, body composition, and medication tolerance. This personalized approach helps connect each treatment choice to the patient’s full metabolic and cardiovascular physiology.
References:
- European Society of Cardiology. 2026 ESC Guidelines for the Management of Heart Failure. European Heart Journal. Published August 28, 2026.
- European Society of Cardiology. 2026 ESC Guidelines on Cardiac Rehabilitation. European Heart Journal. Published August 28, 2026.
- Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022.
- Kosiborod MN, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. 2023.
- Kosiborod MN, et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. New England Journal of Medicine. 2024.
- Packer M, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. 2024.
About Dr. Gerti Tashko, MD
Dr. Gerti Tashko, MD, is an endocrinologist in Montgomery County, Maryland. He is uniquely quadruple board-certified in endocrinology, lipidology, hypertension, and obesity medicine. His practice delivers root-cause-focused metabolic and endocrine care, available virtually and in person. He uses advanced diagnostics, personalized nutrition, and preventive medicine to improve long-term health.
